







































Emmanuel Ifeanyi Obeagu                                                                                                      Asian Journal of Dental and Health Sciences. 2025; 5(1):40-44 

[40]                                                                                                                                                                                                                                              AJDHS.COM 

 

 

Available online at ajdhs.com 

Asian Journal of Dental and Health Sciences 
Open Access to Dental and Medical Research 

Copyright  © 2025 The  Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 
which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the 

original author and source are credited  

 

 

Clinical Utility of Mentzer Index in Pregnancy Anemia Screening Programs: A 
Narrative Review 

Emmanuel Ifeanyi Obeagu *  

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe 

Article Info: 
_____________________________________________ 
Article History: 

Received   10 Nov 2024     
Reviewed  25 Dec 2024 
Accepted   16 Jan 2025 
Published 15 March 2025 

_____________________________________________ 
Cite this article as:  

Obeagu EI, Clinical Utility of Mentzer Index in 
Pregnancy Anemia Screening Programs: A 
Narrative Review, Asian Journal of Dental and 
Health Sciences. 2025; 5(1):40-44                                                                     

DOI: http://dx.doi.org/10.22270/ajdhs.v5i1.118          

Abstract 
_________________________________________________________________________________________________________________ 

Anemia in pregnancy is a prevalent condition that can lead to severe complications for both mothers 
and their fetuses. Differentiating between the causes of anemia, particularly iron deficiency anemia 
(IDA) and thalassemia traits, is crucial for appropriate treatment. The Mentzer Index (MI) is a 
simple, cost-effective tool used to distinguish between these two common causes of microcytic 
anemia by comparing the mean corpuscular volume (MCV) to the red blood cell (RBC) count. This 
review explores the clinical utility of the MI in pregnancy anemia screening programs, highlighting 
its advantages, limitations, and potential role in improving diagnosis and management. The Mentzer 
Index has proven to be an effective first-line diagnostic tool, especially in resource-limited settings 
where advanced testing may not be readily available. By providing a straightforward method to 
differentiate IDA from thalassemia traits, the MI helps prevent the inappropriate use of iron 
supplements, which can exacerbate complications in individuals with thalassemia. Additionally, its 
simplicity allows for its incorporation into routine prenatal care, improving the efficiency of anemia 
screening programs and facilitating early intervention. Despite its benefits, the MI has limitations, 
including its reduced accuracy in pregnancy due to physiological changes and mixed anemia. 

Keywords: Mentzer Index, pregnancy anemia, anemia screening, clinical utility, iron deficiency 
anemia 

*Address for Correspondence:   

Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe 

 

Introduction 

Anemia during pregnancy is a common and significant 
public health concern, affecting a substantial proportion 
of pregnant women worldwide. It is associated with 
numerous adverse outcomes for both the mother and 
fetus, including maternal fatigue, increased risk of 
preterm birth, low birth weight, and even maternal and 
infant mortality in severe cases. According to the World 
Health Organization (WHO), anemia affects around 40% 
of pregnant women globally, with iron deficiency 
anemia (IDA) being the most prevalent cause. Anemia in 
pregnancy is particularly common in low-resource 
settings where dietary deficiencies, parasitic infections, 
and limited access to healthcare services contribute to 
its high prevalence.1-2 The causes of anemia in 
pregnancy are diverse and include iron deficiency, 
vitamin B12 and folate deficiencies, anemia of chronic 
disease, and genetic disorders such as thalassemia. Iron 
deficiency anemia (IDA) is the most common etiology, 
arising due to increased iron requirements during 
pregnancy that exceed the available iron stores. 
Thalassemia, a group of inherited blood disorders 
characterized by abnormal hemoglobin production, is 
also prevalent in certain populations. Microcytic 
anemia, which presents with low mean corpuscular 

volume (MCV), is often seen in both IDA and 
thalassemia, making differential diagnosis challenging. 
Therefore, accurate identification of the underlying 
cause of anemia is essential for effective treatment and 
management.3-4 

Differentiating between IDA and thalassemia is crucial 
because the treatment approaches for these two 
conditions differ significantly. While IDA is treated with 
iron supplementation, thalassemia requires different 
management, such as folic acid supplementation and, in 
some cases, blood transfusions. Misdiagnosis and 
inappropriate treatment, such as the use of iron 
supplementation in individuals with thalassemia, can 
lead to complications such as iron overload. This makes 
the ability to differentiate between these two conditions 
an essential aspect of anemia management during 
pregnancy. In this context, the Mentzer Index (MI) has 
emerged as a simple and effective tool to help 
healthcare providers distinguish between IDA and 
thalassemia traits.5 The Mentzer Index is a calculation 
derived from a complete blood count (CBC), using the 
ratio of the mean corpuscular volume (MCV) to the red 
blood cell (RBC) count. A lower MI value (typically less 
than 13) suggests thalassemia traits, whereas a higher 
value (greater than 13) is indicative of IDA. This 

                     Open Access                                                                                                                                                                                                                Review Article                                                                           

http://jddtonline.info/
http://dx.doi.org/10.22270/ajdhs.v5i1.118
https://crossmark.crossref.org/dialog/?doi=10.22270/ajdhs.v5i1.118&amp;domain=pdf
https://orcid.org/0000-0002-4538-0161


Emmanuel Ifeanyi Obeagu                                                                                                      Asian Journal of Dental and Health Sciences. 2025; 5(1):40-44 

[41]                                                                                                                                                                                                                                              AJDHS.COM 

straightforward formula is easy to calculate and does 
not require specialized equipment, making it an ideal 
tool for use in primary care settings, especially in 
resource-limited environments. Its simplicity, combined 
with the ability to distinguish between two of the most 
common causes of microcytic anemia, makes the MI an 
attractive option for anemia screening in pregnant 
populations.6-7 Despite the advantages of the Mentzer 
Index, it is not without limitations. The MI may not be as 
reliable in certain circumstances, such as when a 
pregnant woman has mixed anemia, where both iron 
deficiency and thalassemia traits coexist. Additionally, 
physiological changes during pregnancy, such as an 
increase in blood volume and alterations in red blood 
cell production, can affect the accuracy of the MI. 
Therefore, while the MI is a valuable screening tool, it 
should not be used in isolation. It must be combined 
with other diagnostic tests and clinical assessments to 
ensure a comprehensive diagnosis.8-9 The clinical utility 
of the Mentzer Index in anemia screening during 
pregnancy is particularly relevant in low-resource 
settings where access to more advanced diagnostic 
tests, such as hemoglobin electrophoresis or genetic 
screening, may be limited. In these contexts, the MI 
offers a practical, affordable, and effective method for 
identifying women at risk of iron deficiency or 
thalassemia. The incorporation of the MI into routine 
prenatal care can enhance early detection and 
management of anemia, potentially improving maternal 
and fetal outcomes. However, further research is needed 
to assess its performance in diverse populations and to 
optimize its use in pregnancy anemia screening 
programs.10-11 

Anemia in Pregnancy 

Anemia in pregnancy is a widespread condition that 
poses significant risks to both maternal and fetal health. 
It is defined as a reduction in hemoglobin levels, which 
can result from a variety of underlying causes. Pregnant 
women are particularly vulnerable to anemia due to 
increased physiological demands, such as the expansion 
of blood volume, increased iron and folate 
requirements, and changes in red blood cell production. 
As a result, anemia during pregnancy is associated with 
numerous complications, including fatigue, weakness, 
preterm labor, low birth weight, and in severe cases, 
maternal and fetal death. The World Health 
Organization (WHO) estimates that anemia affects 
around 40% of pregnant women worldwide, with the 
prevalence varying by region, socioeconomic status, and 
access to healthcare.12-13 The causes of anemia in 
pregnancy are diverse and can be broadly categorized 
into nutritional deficiencies, chronic diseases, and 
genetic disorders. The most common cause of anemia in 
pregnancy is iron deficiency anemia (IDA), which occurs 
when there is insufficient iron to meet the increased 
demand during pregnancy. This is often exacerbated by 
poor dietary intake, malabsorption, or blood loss. Other 
causes include folate deficiency, vitamin B12 deficiency, 
and anemia of chronic disease, which is seen in 
conditions like chronic infections or autoimmune 
disorders. In certain populations, genetic disorders such 
as thalassemia and sickle cell disease can contribute to 

anemia, leading to microcytic or normocytic anemia, 
respectively.14-15 

Anemia during pregnancy can have serious 
consequences for maternal health. It increases the risk 
of preterm delivery, low birth weight, and postpartum 
hemorrhage. For the fetus, it can lead to intrauterine 
growth restriction, low birth weight, and developmental 
delays. Severe anemia has also been associated with an 
increased risk of maternal mortality, especially in low-
resource settings where access to healthcare may be 
limited. Furthermore, maternal anemia can compromise 
the oxygen-carrying capacity of the blood, which in turn 
affects the oxygen supply to both the mother and the 
fetus, leading to potential developmental and health 
issues.16 In addition to these risks, anemia in pregnancy 
can have long-term implications for both the mother 
and child. Women who experience anemia during 
pregnancy are more likely to suffer from postpartum 
anemia, which can delay recovery and impact overall 
health. For children, early exposure to maternal anemia 
has been linked to cognitive and developmental delays. 
As such, anemia management is crucial not only for the 
health of the pregnant woman but also for the long-term 
health and development of the child. Early 
identification, proper screening, and effective treatment 
are key to reducing the burden of anemia in pregnancy 
and improving maternal and fetal outcomes.17 The 
identification and management of anemia during 
pregnancy require accurate diagnosis and 
differentiation between its various causes. This is 
crucial for providing the appropriate treatment. For 
instance, while iron deficiency anemia can be effectively 
managed with iron supplementation, thalassemia traits 
require different management strategies. Misdiagnosis 
and inappropriate treatment, such as administering iron 
supplements to a woman with thalassemia, can lead to 
adverse outcomes, including iron overload. As a result, 
healthcare providers need reliable diagnostic tools to 
distinguish between the causes of anemia in pregnancy 
and ensure targeted treatment.18 

The Role of the Mentzer Index in Pregnancy 
Anemia Screening 

The Mentzer Index (MI) is a valuable diagnostic tool 
used to differentiate between two common causes of 
microcytic anemia: iron deficiency anemia (IDA) and 
thalassemia. During pregnancy, anemia is a prevalent 
condition that can lead to serious complications for both 
the mother and fetus. Differentiating between the 
causes of anemia is crucial, as the treatment for IDA 
(iron supplementation) differs significantly from the 
management of thalassemia (which may require folic 
acid supplementation and careful monitoring to avoid 
iron overload). The Mentzer Index has become an 
important part of anemia screening, particularly in 
resource-limited settings, due to its simplicity, cost-
effectiveness, and ability to provide immediate insight 
into the cause of anemia.19 The Mentzer Index is 
calculated by dividing the mean corpuscular volume 
(MCV) by the red blood cell (RBC) count, which is 
expressed as a ratio. A lower MI value, generally below 
13, is indicative of thalassemia or other 



Emmanuel Ifeanyi Obeagu                                                                                                      Asian Journal of Dental and Health Sciences. 2025; 5(1):40-44 

[42]                                                                                                                                                                                                                                              AJDHS.COM 

hemoglobinopathies, while a higher MI value, greater 
than 13, typically suggests iron deficiency anemia. This 
differentiation is particularly important in pregnancy 
because iron supplementation, which is effective for 
treating IDA, can exacerbate iron overload in individuals 
with thalassemia. The MI is a simple calculation, 
requiring only basic hematological parameters from a 
complete blood count (CBC), making it easy to use in 
clinical practice, particularly in primary care and low-
resource settings where advanced diagnostic tools may 
not be available.20 

The application of the Mentzer Index in pregnancy 
anemia screening can improve diagnostic accuracy and 
allow for more targeted interventions. Early 
differentiation between IDA and thalassemia can help 
avoid the inappropriate administration of iron 
supplements to women with thalassemia, preventing 
potential complications such as iron overload. 
Moreover, the MI aids in the identification of women 
who may require further diagnostic tests, such as 
hemoglobin electrophoresis or genetic screening, to 
confirm the presence of thalassemia or other 
hemoglobinopathies. This allows for more efficient use 
of healthcare resources and ensures that pregnant 
women receive the most appropriate and effective 
treatment for their condition.21 In the context of 
pregnancy, where maternal and fetal health is at stake, 
the role of the Mentzer Index becomes even more 
significant. Pregnancy is a time of increased iron 
demand, and iron deficiency anemia is one of the most 
common conditions affecting pregnant women. By 
providing a simple and quick means of distinguishing 
between IDA and thalassemia, the MI enables healthcare 
providers to initiate the correct treatment earlier, 
reducing the risk of adverse outcomes. Furthermore, the 
MI helps clinicians identify women who may benefit 
from more comprehensive genetic counseling and 
screening, particularly in regions with higher 
prevalence rates of thalassemia.22 

Advantages and Limitations of the Mentzer 
Index in Pregnancy Anemia Screening 

The Mentzer Index (MI) is a practical and cost-effective 
tool used in the screening of anemia during pregnancy, 
particularly for distinguishing between iron deficiency 
anemia (IDA) and thalassemia, two of the most common 
causes of microcytic anemia. While the MI offers several 
advantages in clinical practice, it also comes with 
limitations that need to be considered for accurate and 
effective application in anemia management. 
Understanding both its strengths and weaknesses can 
help clinicians make more informed decisions when 
using the MI in pregnancy anemia screening.23 

Advantages 

1. Simplicity and Ease of Use 

One of the key advantages of the Mentzer Index is its 
simplicity. It is calculated using two basic parameters 
obtained from a complete blood count (CBC): mean 
corpuscular volume (MCV) and red blood cell (RBC) 
count. These parameters are readily available in most 
clinical settings, making the MI an easy and quick tool to 

use without the need for complex or expensive 
diagnostic equipment. This simplicity makes it 
especially valuable in primary care settings or low-
resource environments where access to advanced 
testing may be limited.24 

2. Cost-Effective 

The Mentzer Index is a highly cost-effective method for 
differentiating between IDA and thalassemia. Unlike 
more specialized diagnostic tests, such as hemoglobin 
electrophoresis or genetic screening, which can be 
costly and may require specialized facilities, the MI 
relies on parameters that are already part of routine 
blood tests. This makes it an attractive option for 
healthcare systems with limited resources, allowing for 
early and efficient screening of anemia in pregnant 
women.25 

3. Early Differentiation Between IDA and 
Thalassemia 

The MI is particularly useful in distinguishing between 
IDA and thalassemia, two conditions that can present 
similarly with microcytic anemia. Iron deficiency 
anemia, which is treated with iron supplementation, is 
the most common form of anemia in pregnancy, while 
thalassemia requires different management strategies. 
The MI helps avoid the mismanagement of thalassemia, 
such as inappropriate iron supplementation, which can 
lead to iron overload. Early differentiation between 
these conditions allows for appropriate treatment and 
reduces the risk of complications for both the mother 
and fetus.26 

4. Applicable in Resource-Limited Settings 

In many low-resource settings, where more advanced 
diagnostic tests may not be available, the Mentzer Index 
provides a simple and accessible alternative. It is 
especially helpful in areas where the prevalence of 
thalassemia or iron deficiency is high. The ability to 
perform quick screenings with a basic CBC and interpret 
the results effectively allows healthcare providers to 
better manage anemia in pregnant women in these 
regions, improving maternal and fetal health 
outcomes.27 

Limitations 

1. Influence of Pregnancy-Related Physiological 
Changes 

Pregnancy itself brings about significant physiological 
changes, such as an increase in blood volume, changes 
in red blood cell production, and alterations in iron 
metabolism. These changes can affect the mean 
corpuscular volume (MCV) and red blood cell (RBC) 
count, potentially leading to misleading Mentzer Index 
results. For example, the increase in plasma volume 
during pregnancy may result in lower RBC 
concentration and altered MCV values, which can distort 
the MI calculation and reduce its diagnostic accuracy in 
pregnant women.24 

 

 



Emmanuel Ifeanyi Obeagu                                                                                                      Asian Journal of Dental and Health Sciences. 2025; 5(1):40-44 

[43]                                                                                                                                                                                                                                              AJDHS.COM 

2. Less Effective in Mixed Anemia 

The MI may be less reliable in cases of mixed anemia, 
where a pregnant woman has both iron deficiency and 
thalassemia traits. In such cases, the MI may produce 
ambiguous results, as both conditions can affect MCV 
and RBC count. Since the MI is designed to distinguish 
between iron deficiency and thalassemia specifically, it 
may not be able to provide a clear diagnosis when both 
conditions are present, necessitating further diagnostic 
testing such as hemoglobin electrophoresis or genetic 
screening for a more definitive diagnosis.25 

3. Limited in Severe Cases of Anemia 

In cases of severe anemia, where hemoglobin levels are 
critically low, the Mentzer Index may not offer reliable 
results. The formula depends on accurate RBC and MCV 
measurements, which can be influenced by extremely 
low or high values of these parameters. For example, in 
severe iron deficiency anemia, the RBC count may be 
elevated as a compensatory mechanism, and in severe 
thalassemia, the RBC count may be disproportionately 
low. These extreme values can cause the MI to be less 
accurate in such scenarios.26 

4. Not Suitable for All Anemia Causes 

While the Mentzer Index is effective in distinguishing 
between IDA and thalassemia, it does not provide 
information on other causes of anemia that may also 
affect pregnant women, such as vitamin B12 deficiency, 
folate deficiency, or anemia of chronic disease. 
Therefore, the MI is only useful for identifying specific 
types of microcytic anemia and should not be relied 
upon as the sole diagnostic tool in cases where other 
etiologies are suspected. A comprehensive approach, 
including additional testing and clinical evaluation, is 
necessary to accurately diagnose and treat anemia with 
multiple underlying causes.27 

5. Need for Additional Diagnostic Confirmation 

While the MI is a useful screening tool, it is not 
definitive. The results should always be corroborated 
with other diagnostic tests, especially in ambiguous or 
borderline cases. For instance, confirmation of 
thalassemia typically requires hemoglobin 
electrophoresis or genetic testing to accurately identify 
the specific hemoglobin variant or mutation. Similarly, 
iron deficiency anemia diagnosis may need additional 
assessments, such as serum ferritin levels or iron 
studies, to confirm the deficiency and assess the 
severity.27 

Conclusion 

The Mentzer Index (MI) serves as a valuable, cost-
effective tool in the screening and differentiation of 
microcytic anemia, particularly for distinguishing 
between iron deficiency anemia (IDA) and thalassemia 
in pregnant women. Its simplicity and accessibility 
make it an ideal choice for use in clinical settings, 
especially in low-resource environments where 
advanced diagnostic tests may be limited. By enabling 
early identification of these two common causes of 
microcytic anemia, the MI helps guide appropriate 

treatment strategies, reducing the risk of complications 
such as iron overload in thalassemia patients. 

Conflict of Interest: Author declares no potential 

conflict of interest with respect to the contents, 

authorship, and/or publication of this article. 

Source of Support: Nil 

Funding: The authors declared that this study has 

received no financial support. 

Informed Consent Statement: Not applicable.  

Data Availability Statement: The data supporting in 

this paper are available in the cited references.  

Ethics approval: Not applicable. 

References 

1. Rahman MM, Abe SK, Rahman MS, Kanda M, Narita S, Bilano V, Ota 
E, Gilmour S, Shibuya K. Maternal anemia and risk of adverse birth 
and health outcomes in low-and middle-income countries: 
systematic review and meta-analysis. The American journal of 
clinical nutrition. 2016; 103(2):495-504. 
https://doi.org/10.3945/ajcn.115.107896 PMid:26739036 

2. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias 
of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 
2016;3(3):10-18. https://doi.org/10.22270/ijmspr.v10i2.95 

3. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, 
Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. 
Iron Status of Pregnant and Post-Partum Women with Malaria 
Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and 
Laboratory Research. 2017;5(4):206. 

4. Petrakos G, Andriopoulos P, Tsironi M. Pregnancy in women with 
thalassemia: challenges and solutions. International journal of 
women's health. 2016:441-451. 
https://doi.org/10.2147/IJWH.S89308 PMid:27660493 
PMCid:PMC5019437 

5. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala 
PU, Agu CC. Assessment of Haematological Changes in Pregnant 
Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021 
Apr;9(4):145-148. 

6. Agreen FC, Obeagu EI. Anaemia among pregnant women: A review 
of African pregnant teenagers. Journal of Public Health and 
Nutrition. 2023;6(1):138. 

7. Arora S, Rana D, Kolte S, Dawson L, Dhawan I. Validation of new 
indices for differentiation between iron deficiency anemia and 
beta thalessemia trait, a study in pregnant females. International 
Journal of Scientific Reports. 2018; 4(2):26. 
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20180394 

8. Obeagu EI, Obeagu GU, Insights into Maternal Health: Mentzer Index 
for Early Anemia Detection, International Journal of Medical 
Sciences and Pharma Research,2024;10(4):44-49 
https://doi.org/10.22270/ijmspr.v10i4.122 

9. Obeagu EI, Influence of Hemoglobin Variants on Vaso-Occlusive 
Phenomena in Sickle Cell Anemia: A Review, International Journal 
of Medical Sciences and Pharma Research, 2024;10(2):54-59 
https://doi.org/10.22270/ijmspr.v10i2.104 

10. Iolascon A, Andolfo I, Russo R, Sanchez M, Busti F, Swinkels D, 
Aguilar Martinez P, Bou‐Fakhredin R, Muckenthaler MU, Unal S, 
Porto G. Recommendations for diagnosis, treatment, and 
prevention of iron deficiency and iron deficiency anemia. 
Hemasphere. 2024; 8(7):e108. 
https://doi.org/10.1002/hem3.108 PMid:39011129 
PMCid:PMC11247274 

11. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. 
Evaluation of protein C, protein S and fibrinogen of pregnant 
women with malaria in Owerri metropolis. Madonna University 

https://doi.org/10.3945/ajcn.115.107896
https://doi.org/10.22270/ijmspr.v10i2.95
https://doi.org/10.2147/IJWH.S89308
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20180394
https://doi.org/10.22270/ijmspr.v10i4.122
https://doi.org/10.22270/ijmspr.v10i2.104
https://doi.org/10.1002/hem3.108


Emmanuel Ifeanyi Obeagu                                                                                                      Asian Journal of Dental and Health Sciences. 2025; 5(1):40-44 

[44]                                                                                                                                                                                                                                              AJDHS.COM 

journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 
Apr 19;2(2):1-9. 

12. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to 
Mothers with Severe Malaria, HIV, and Transfusion History: A 
Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 
38-58 

13. Sahli CA, Bibi A, Ouali F, Fredj SH, Dakhlaoui B, Othmani R, Laouini 
N, Jouini L, Ouenniche F, Siala H, Touhami I. Red cell indices: 
differentiation between β-thalassemia trait and iron deficiency 
anemia and application to sickle-cell disease and sickle-cell 
thalassemia. Clinical Chemistry and Laboratory Medicine (CCLM). 
2013; 51(11):2115-24. https://doi.org/10.1515/cclm-2013-0354 
PMid:23800659 

14. Hoffmann JJ, Nabbe KC, van den Broek NM. Effect of age and 
gender on reference intervals of red blood cell distribution width 
(RDW) and mean red cell volume (MCV). Clinical Chemistry and 
Laboratory Medicine (CCLM). 2015; 53(12):2015-9. 
https://doi.org/10.1515/cclm-2015-0155 PMid:26536583 

15. Miftahussurur M, Husada D, Ningtyas WS. Association Association 
Of Shine and Lal Index Β-Thalassemia Trait Screening Results with 
Anaemia and Low Birth Weigh. International Journal of Nursing 
And Midwifery Science (IJNMS). 2023; 7(3):290-296. 
https://doi.org/10.29082/IJNMS/2023/Vol7/Iss3/543 

16. Shahid H, Saleem M, Naseer N, Tabussam S, Aziz A, Ullah S. 
Evaluation of Srivastava index to distinguishing Beta-Thalassemia 
Trait from Iron Deficiency. Pakistan Journal of Medical & Health 
Sciences. 2022;16(05):1225. 
https://doi.org/10.53350/pjmhs221651225 

17. Vehapoglu A, Ozgurhan G, Demir AD, Uzuner S, Nursoy MA, 
Turkmen S, Kacan A. Hematological indices for differential 
diagnosis of Beta thalassemia trait and iron deficiency anemia. 
Anemia. 2014; 2014(1):576738. 
https://doi.org/10.1155/2014/576738 PMid:24818016 
PMCid:PMC4003757 

18. Urrechaga E. Discriminant value of% microcytic/% hypochromic 
ratio in the differential diagnosis of microcytic anemia. Clinical 
chemistry and laboratory medicine. 2008;46(12):1752-1758. 
https://doi.org/10.1515/CCLM.2008.355 PMid:19055451 

19. Obeagu EI, Obeagu GU, Anemia in Pregnancy: Mentzer Index as a 
Predictor for Iron Supplementation Needs, International Journal 
of Medical Sciences and Pharma Research, 2024;10(4):39-43 
https://doi.org/10.22270/ijmspr.v10i4.121 

20. Obeagu EI, Obeagu GU. Sickle cell anaemia in pregnancy: a review. 
International Research in Medical and Health Sciences. 2023 Jun 
10;6(2):10-13. https://doi.org/10.22270/ijmspr.v10i2.103 

21. Obeagu EI, Ubosi NI, Uzoma G. Antioxidant Supplementation in 
Pregnancy: Effects on Maternal and Infant Health. Int. J. Adv. 
Multidiscip. Res. 2023;10(11):60-70. 

22. Obeagu EI, Obeagu GU. Mitigating Oxidative Stress in Pregnancy 
through Antioxidant Supplementation: A Narrative Review. Int. J. 
Curr. Res. Chem. Pharm. Sci. 2024;11(9):7-17. 

23. Obeagu EI, Obeagu GU. Enhancing Maternal and Fetal Well-being: 
The Role of Antioxidants in Pregnancy. Elite Journal of Medical 
Sciences. 2024;2(4):76-87. 

24. Obeagu EI, Obeagu GU. Antioxidant Supplementation and 
Prevention of Early Pregnancy Loss: A Narrative Review. Int. J. 
Curr. Res. Chem. Pharm. Sci. 2024;11(9):28-37. 
https://doi.org/10.22270/ijmspr.v10i4.120 

25. Obeagu EI, Obeagu GU. Molar Pregnancy: Update of prevalence and 
risk factors. Int. J. Curr. Res. Med. Sci. 2023;9(7):25-28. 
https://doi.org/10.19080/JGWH.2023.25.556169 

26. Obeagu EI, Obeagu GU. Hypoxia-induced Metabolic Changes in 
Pregnancy: Clinical Perspectives. Elite Journal of Medicine. 
2024;2(8):50-59. 

27. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women 
with Sickle Cell Anemia: A Review. Elite Journal of Haematology. 
2024;2(3):67-80. 

 

 

https://doi.org/10.1515/cclm-2013-0354
https://doi.org/10.1515/cclm-2015-0155
https://doi.org/10.29082/IJNMS/2023/Vol7/Iss3/543
https://doi.org/10.53350/pjmhs221651225
https://doi.org/10.1155/2014/576738
https://doi.org/10.1515/CCLM.2008.355
https://doi.org/10.22270/ijmspr.v10i4.121
https://doi.org/10.22270/ijmspr.v10i2.103
https://doi.org/10.22270/ijmspr.v10i4.120
https://doi.org/10.19080/JGWH.2023.25.556169

